These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26797420)

  • 1. Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer.
    Sharma MC; Tuszynski GP; Blackman MR; Sharma M
    Cancer Lett; 2016 Apr; 373(1):27-35. PubMed ID: 26797420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
    Sharma M; Blackman MR; Sharma MC
    Exp Mol Pathol; 2012 Feb; 92(1):175-84. PubMed ID: 22044461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers.
    Sharma MC
    Int J Cancer; 2019 May; 144(9):2074-2081. PubMed ID: 30125343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Important role of annexin A2 (ANXA2) in new blood vessel development in vivo and human triple negative breast cancer (TNBC) growth.
    Sharma MC; Jain D
    Exp Mol Pathol; 2020 Oct; 116():104523. PubMed ID: 32866522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomal Annexin II Promotes Angiogenesis and Breast Cancer Metastasis.
    Maji S; Chaudhary P; Akopova I; Nguyen PM; Hare RJ; Gryczynski I; Vishwanatha JK
    Mol Cancer Res; 2017 Jan; 15(1):93-105. PubMed ID: 27760843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
    Sharma MC; Sharma M
    Curr Pharm Des; 2007; 13(35):3568-75. PubMed ID: 18220793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.
    Sharma M; Ownbey RT; Sharma MC
    Exp Mol Pathol; 2010 Apr; 88(2):278-86. PubMed ID: 20079732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action.
    Sharma MR; Rothman V; Tuszynski GP; Sharma MC
    Exp Mol Pathol; 2006 Oct; 81(2):136-45. PubMed ID: 16643891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression.
    Sharma MR; Koltowski L; Ownbey RT; Tuszynski GP; Sharma MC
    Exp Mol Pathol; 2006 Oct; 81(2):146-56. PubMed ID: 16643892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
    J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
    Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
    BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer.
    Mukerjee A; Ranjan AP; Vishwanatha JK
    J Biomed Nanotechnol; 2016 Jul; 12(7):1374-92. PubMed ID: 29336533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies.
    Chaudhary P; Thamake SI; Shetty P; Vishwanatha JK
    Br J Cancer; 2014 Dec; 111(12):2328-41. PubMed ID: 25321192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo.
    Sun Y; Wang X; Zhou Q; Lu Y; Zhang H; Chen Q; Zhao M; Su S
    Oncol Rep; 2015 Jan; 33(1):338-46. PubMed ID: 25370743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo.
    Zhang L; Kim S; Ding W; Tong Y; Zhang X; Pan M; Chen S
    Drug Des Devel Ther; 2015; 9():5579-90. PubMed ID: 26487802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.
    Qiu M; Peng Q; Jiang I; Carroll C; Han G; Rymer I; Lippincott J; Zachwieja J; Gajiwala K; Kraynov E; Thibault S; Stone D; Gao Y; Sofia S; Gallo J; Li G; Yang J; Li K; Wei P
    Cancer Lett; 2013 Jan; 328(2):261-70. PubMed ID: 23041621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.
    Shetty P; Patil VS; Mohan R; D'souza LC; Bargale A; Patil BR; Dinesh US; Haridas V; Kulkarni SP
    Ann Clin Biochem; 2017 Jul; 54(4):463-471. PubMed ID: 27496793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.